These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35397664)

  • 41. Real-world evidence of poly ADP-ribose polymerase inhibitors in the treatment of ovarian cancer: A systematic literature review.
    Borrelli EP; McGladrigan CG
    J Oncol Pharm Pract; 2020 Dec; 26(8):1977-1986. PubMed ID: 32659172
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance.
    Lorusso D; García-Donas J; Sehouli J; Joly F
    Target Oncol; 2020 Jun; 15(3):391-406. PubMed ID: 32495160
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors.
    Rolfo C; Swaisland H; Leunen K; Rutten A; Soetekouw P; Slater S; Verheul HM; Fielding A; So K; Bannister W; Dean E
    Adv Ther; 2015 Jun; 32(6):510-22. PubMed ID: 26048134
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Novel pharmacological effects of poly (ADP-ribose) polymerase inhibitor rucaparib on the lactate dehydrogenase pathway.
    Nonomiya Y; Noguchi K; Katayama K; Sugimoto Y
    Biochem Biophys Res Commun; 2019 Mar; 510(4):501-507. PubMed ID: 30737031
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours.
    Plummer R; Swaisland H; Leunen K; van Herpen CM; Jerusalem G; De Grève J; Lolkema MP; Soetekouw P; Mau-Sørensen M; Nielsen D; Spicer J; Fielding A; So K; Bannister W; Molife LR
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):723-9. PubMed ID: 26242220
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Utilization of Poly(ADP-Ribose) Polymerase Inhibitors in Ovarian Cancer: A Retrospective Cohort Study of US Healthcare Claims Data.
    Arend RC; O'Malley DM; Banerjee S; McLaurin K; Davidson R; Long GH
    Adv Ther; 2022 Jan; 39(1):328-345. PubMed ID: 34727316
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
    Rolfo C; de Vos-Geelen J; Isambert N; Molife LR; Schellens JHM; De Grève J; Dirix L; Grundtvig-Sørensen P; Jerusalem G; Leunen K; Mau-Sørensen M; Plummer R; Learoyd M; Bannister W; Fielding A; Ravaud A
    Clin Pharmacokinet; 2019 Sep; 58(9):1165-1174. PubMed ID: 30877569
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors.
    Liao M; Jeziorski KG; Tomaszewska-Kiecana M; Láng I; Jasiówka M; Skarbová V; Centkowski P; Ramlau R; Górnaś M; Lee J; Edwards S; Habeck J; Nash E; Grechko N; Xiao JJ
    Cancer Chemother Pharmacol; 2021 Nov; 88(5):887-897. PubMed ID: 34370076
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.
    Alvarez Secord A; O'Malley DM; Sood AK; Westin SN; Liu JF
    Gynecol Oncol; 2021 Aug; 162(2):482-495. PubMed ID: 34090705
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial.
    Konstantinopoulos PA; Barry WT; Birrer M; Westin SN; Cadoo KA; Shapiro GI; Mayer EL; O'Cearbhaill RE; Coleman RL; Kochupurakkal B; Whalen C; Curtis J; Farooq S; Luo W; Eismann J; Buss MK; Aghajanian C; Mills GB; Palakurthi S; Kirschmeier P; Liu J; Cantley LC; Kaufmann SH; Swisher EM; D'Andrea AD; Winer E; Wulf GM; Matulonis UA
    Lancet Oncol; 2019 Apr; 20(4):570-580. PubMed ID: 30880072
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rucaparib in the landscape of PARP inhibition in ovarian cancer.
    Colomba E; Pautier P; Pommeret F; Leary A
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):437-446. PubMed ID: 30977683
    [No Abstract]   [Full Text] [Related]  

  • 52. Population pharmacokinetic analysis of tepotinib, an oral MET kinase inhibitor, including data from the VISION study.
    Xiong W; Papasouliotis O; Jonsson EN; Strotmann R; Girard P
    Cancer Chemother Pharmacol; 2022 May; 89(5):655-669. PubMed ID: 35385993
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of food on the pharmacokinetics of niraparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with recurrent ovarian cancer.
    Moore K; Zhang ZY; Agarwal S; Burris H; Patel MR; Kansra V
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):497-503. PubMed ID: 29322231
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Latest clinical evidence of maintenance therapy in ovarian cancer.
    Walsh CS
    Curr Opin Obstet Gynecol; 2020 Feb; 32(1):15-21. PubMed ID: 31833941
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious
    Balasubramaniam S; Beaver JA; Horton S; Fernandes LL; Tang S; Horne HN; Liu J; Liu C; Schrieber SJ; Yu J; Song P; Pierce W; Robertson KJ; Palmby TR; Chiu HJ; Lee EY; Philip R; Schuck R; Charlab R; Banerjee A; Chen XH; Wang X; Goldberg KB; Sridhara R; Kim G; Pazdur R
    Clin Cancer Res; 2017 Dec; 23(23):7165-7170. PubMed ID: 28751443
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Preclinical Studies on the Effect of Rucaparib in Ovarian Cancer: Impact of BRCA2 Status.
    Saravi S; Alizzi Z; Tosi S; Hall M; Karteris E
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572083
    [TBL] [Abstract][Full Text] [Related]  

  • 57. When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials.
    Antonarakis ES; Gomella LG; Petrylak DP
    Eur Urol Oncol; 2020 Oct; 3(5):594-611. PubMed ID: 32814685
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairment.
    Rolfo C; Isambert N; Italiano A; Molife LR; Schellens JHM; Blay JY; Decaens T; Kristeleit R; Rosmorduc O; Demlova R; Lee MA; Ravaud A; Kopeckova K; Learoyd M; Bannister W; Locker G; de Vos-Geelen J
    Br J Clin Pharmacol; 2020 Sep; 86(9):1807-1818. PubMed ID: 32227355
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) restrict oral availability and brain accumulation of the PARP inhibitor rucaparib (AG-014699).
    Durmus S; Sparidans RW; van Esch A; Wagenaar E; Beijnen JH; Schinkel AH
    Pharm Res; 2015 Jan; 32(1):37-46. PubMed ID: 24962512
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer.
    Liao M; Zhou J; Wride K; Lepley D; Cameron T; Sale M; Xiao J
    Eur J Drug Metab Pharmacokinet; 2022 Sep; 47(5):711-723. PubMed ID: 35844029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.